NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis ; volume:38 ; number:5 ; year:2015 ; pages:221-229
Oncology research and treatment ; 38, Heft 5 (2015), 221-229
- Urheber
-
Kurbacher, Christian M.
Fietz, Thomas
Diel, Ingo J.
Egert, Matthias
Hurtz, Hans-Jürgen
Lück, Andreas
Weide, Rudolf
Salat, Christoph
Wolff, Thomas
Zaiss, Matthias
Klare, Peter
Losem, Christoph
Illmer, Thomas
WeißEnborn, Georg
Steffens, Claus-Christoph
Schulze, Matthias
Tesch, Hans
Oskay-Oezcelik, Gülten
Teichmann, Beate
Harde, Johanna
Scheuerlein, Robert Willy
- DOI
-
10.1159/000381631
- URN
-
urn:nbn:de:101:1-2017120814778
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:19 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kurbacher, Christian M.
- Fietz, Thomas
- Diel, Ingo J.
- Egert, Matthias
- Hurtz, Hans-Jürgen
- Lück, Andreas
- Weide, Rudolf
- Salat, Christoph
- Wolff, Thomas
- Zaiss, Matthias
- Klare, Peter
- Losem, Christoph
- Illmer, Thomas
- WeißEnborn, Georg
- Steffens, Claus-Christoph
- Schulze, Matthias
- Tesch, Hans
- Oskay-Oezcelik, Gülten
- Teichmann, Beate
- Harde, Johanna
- Scheuerlein, Robert Willy
Ähnliche Objekte (12)
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
Nadir
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
Nadir
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases